Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 720 results for pain management

  1. Laser therapy for chronic primary pain: What is the clinical and cost effectiveness of laser therapy for managing chronic primary pain in people aged 16 years and over?

    therapy for chronic primary pain: What is the clinical and cost effectiveness of laser therapy for managing chronic primary...

  2. Psychological therapy – mindfulness for chronic primary pain: What is the clinical and cost effectiveness of mindfulness therapy for managing chronic primary pain in people aged 16 years and over?

    mindfulness for chronic primary pain: What is the clinical and cost effectiveness of mindfulness therapy for managing chronic primary...

  3. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  4. Factors affecting participation and quality of life:- What are the key factors, including additional care and support, that influence participation and quality of life in people with neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) Why this is important:- There is evidence suggesting that people with neuropathic...

  5. Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

    This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

  6. Endoscopic transluminal pancreatic necrosectomy (HTG421)

    Evidence-based recommendations on endoscopic transluminal pancreatic necrosectomy in adults. This involves removing dead tissue from the pancreas.

  7. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  8. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  9. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The World...

  10. Thoracoscopic repair of congenital diaphragmatic hernia in neonates (HTG247)

    Evidence-based recommendations on thoracoscopic repair of congenital diaphragmatic hernia in neonates. This involves inserting surgical instruments through small cuts in the chest, and then moving the abdominal organs out of the chest and repairing the diaphragm.

  11. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (HTG222)

    Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.

  12. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

  13. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

  14. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

  15. Potential for dependence associated with pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic...